My meeting days all started with picking up a bite to eat in the Patient Lounge. The lounge was a great place to meet up with other advocates from around the world, relax is comfy chairs and pick up a bite to eat at breakfast or lunch.
Sunday started with the Gyn Cancer Oral Abstract Session followed by an afternoon of meeting with clinicians I am working with as well as learning about Patient Story .
Clear Cell OC
BrUOG 354 ph 2 Nivulomab alone or w ipilimumab in clear cell OC mutation -TP53 ,ARID1A PIK3CA
— Dee Sparacio (@womenofteal) June 2, 2024
10% OC cells are clear cell ,
44 patients, hypothyroidism AE.
Combo better than single agent
Nivo ORR 14month combo 33 months pic.twitter.com/HksVonCyey
Recurrent OC no additional benefits from adding Atezolizumab
AGO-OVAR 2.29 Atezolizumab study
— Dee Sparacio (@womenofteal) June 2, 2024
OS atezo arm 14.2 months vs 13.0 placebo arm
AES higher in Atezo arm #ASCO24 #gyncsm pic.twitter.com/GXDpeF2dG7
Endometrial Cancer
#ASCO24 #gyncsm KEYVIBE 005 study
— Dee Sparacio (@womenofteal) June 2, 2024
vibostolimab with pembro in recurrent dMMR endometrial cancer
antiTIGIT antibody
ORR 65% w 75% response greater than 1 year
OS not reached pic.twitter.com/TuEO356CV6
Keyvibe-005 trial-cohort 1b- anti TIGIT vibostolimab + Pembro in MMRd, IO naive #EmCA after at least 1 line platinum- ORR 65% w/ DOR 75% at >1 year. Will wait to see ongoing DOR as ORR in RUBY 77% vs NRG018 57% in this MMRd population with higher median PFS...#ASCO24 #gyncsm pic.twitter.com/DDVmOUN8Z7
— Dr.Monica Avila (@MAvilaMD) June 2, 2024
Pharma support of trials
#ASCO24 #gyncsm Ruan : Study oversight in ph3 gyn onc trials
— Dee Sparacio (@womenofteal) June 2, 2024
Pharma support of trials has increased over the past 12 years . Higher COI in US than Europe
Hispanic and Black enrollment remains low pic.twitter.com/Z3MGRyC4vP
When Bad News Comes Through the Portal ... Education Session
#ASCO24 #gyncsm
— Dee Sparacio (@womenofteal) June 2, 2024
Dr Hubbard speaking on receiving information on the patient portal.
improved knowledge , patients more engaged , review charts for accuracy . How to address anxiety? How to clinicians pic.twitter.com/Bf2v28f0TP
#ASCO24 amazing advocate @TheLizArmy #btsm speaking now on using the patient portal and sharing her story and Open Notes #gyncsm pic.twitter.com/xQ5ki55akB
— Dee Sparacio (@womenofteal) June 2, 2024
Exploring the Uncommon: What's New in Rare Gyn Cancers - Low grade serous , Melanoma of the gyn tract and neuroendocrine carcinomas of the cervix
Gourley discussing low grade serous OC treatments: MAPK assoc tumors better outcomes. Endocrine treatment studies being done.MEk inhibitors more work needs to be done. CDK 4/6 inhibitors possible #ASCO24 #gyncsm pic.twitter.com/qlcd50KFhV
— Dee Sparacio (@womenofteal) June 2, 2024
#gyncsm #ASCO24
— Dee Sparacio (@womenofteal) June 2, 2024
Au-Yeung : Melanomas in the gyn tract -rare disease
No consensus on staging
Novel therapies being tested. pic.twitter.com/jpWTHDnitD
#ASCO24 #gyncsm @amandanfader on neuroendocrine carcinoma of the cervix
— Dee Sparacio (@womenofteal) June 2, 2024
Rare tumor cancers need collaboration between cancer centers
Most NECC are HPV related @SGO_org has guidelines for NECC .
Swog S2012 study of plat/ etoposide/ atezolizumab enrolling pic.twitter.com/0XAKsYZtwn
Obesity and Endometrial Cancer
#gyncsm #asco2024 Great abstract reemphasizing links between obesity& #endometrialcancer &very concerning trends increasing EC younger pts.Interventions&education along the entire reproductive health tract across all age groups are needed. Pcp , OB/GYN, Gynonc, endo, bariatrics pic.twitter.com/KgDyaqWPIh
— Nita Lee (@NitaKarnikLee) June 2, 2024
Cervical Cancer
#ASCO24 RTOG 0724 results confirm the findings of GOG 274- no role for adjuvant chemotherapy to follow chemo/RT in any setting for cervical cancer. Our next question is the role of NEO-adjuvant chemo vs chemo/io - this remains a key clinical question. pic.twitter.com/KTro49kiHK
— DrKatyMoore (@DrKatyMoore) June 2, 2024
GOG0724- chemoRT followed by chemo does not meet endpoints in patients with high risk stage 1A2, IB, 2A cervical cancers after radical hyst with majority IB with 70% + PA nodes with 26% not receiving treatment in chemo addition arm due to self dc #ASCO24 #gyncsm pic.twitter.com/9WXTmnnHsS
— Dr.Monica Avila (@MAvilaMD) June 2, 2024
Metastatic disease clinical trials
Critical points to consider to advance truly patient-centered clinical trials with outcomes that matter
— Ophira Ginsburg (@OphiraG) June 3, 2024
By the @EORTC President Dr. @Winette_vdGraaf @csoncol pic.twitter.com/FbaUeXvS6n
Tomorrow I'll review a few of the posters as well as a round-up of the connections I made.
Dee
Every Day is a Blessing!
No comments:
Post a Comment